Tight Glycemic Control in Critically Ill Patients

To the Editor: Recently published trials of tight glycemic control in critically ill patients have documented lack of treatment benefit and frequent severe hypoglycemia. The NICE-SUGAR trial raised the question of potential treatment-related harm and also documented significant hypoglycemia. The COIITSS Study evaluated intensive insulin therapy in critically ill patients with sepsis who were treated with glucocorticoids and reported a high incidence of hypoglycemia (16.4% vs 7.8% in the conventional treatment group) without apparent benefit. These large complex multicenter trials that evaluated insulin therapy during critical illness consistently demonstrated high rates of hypoglycemia with tight insulin therapy. However, they did not investigate the possibility of identifying patient subpopulations at increased risk for treatment-related hypoglycemia.

Control of hyperglycemia during critical illness has become a standard of care. Although optimal glucose targets and protocols continue to be examined, hypoglycemia is a recurrent complication reported in all key clinical trials. Identifying which patients are at increased risk for hypoglycemia may improve patient safety. A factor that may influence the risk and benefit of insulin therapy is prehospital glycemic status. The COIITSS study and previous trials tended to treat critically ill patients with hyperglycemia as a single cohort, yet these patients are a heterogeneous population of individuals with known diabetes, with prediabetes, and with no prior history of a disorder of glucose metabolism. Multicenter randomized trials have not considered prehospital glycemic status as an important variable that may affect hypoglycemia risk during treatment. Defining patient characteristics better may reduce complications of treatment and maximize benefit.

Mario R. Castellanos, MD
mario_md@yahoo.com
Jeffrey Rothman, MD
Morton Kleiner, MD
Department of Medicine
Staten Island University Hospital
Staten Island, New York

Financial Disclosures: Dr. Rothman reported receiving honoraria as part of speaker programs for Sanofi-Aventis, Novo Nordisk, Eli Lilly, and Takeda. No other disclosures were reported.


In Reply: Since the 2001 study by van den Berghe et al,1 practices in the intensive care unit have been altered toward avoiding persistent hyperglycemia. Since then, our study and others2 have provided additional evidence suggesting that normalization of blood glucose levels should not be a target, at least with tools available at the bedside. As pointed out by Dr. Castellanos and colleagues, hypoglycemia may be the price of blood glucose control. In the COIITSS trial, a total of 62 patients experienced a total of 108 episodes of hypoglycemia, ranging from 1 to 10 per patient. Of these patients, 51 were hypoglycemic on a single day, 10 had hypoglycemic episodes on 2 distinct days, and 1 patient had this complication occurring over 4 days. These findings suggest that hypoglycemia may be predominantly a complication of the initiation of intensive insulin therapy. In the COIITSS trial, this complication was not associated with an increased risk of death.

At day 7, the cumulative incidence of first hypoglycemia was 12.3%, with a 7-day cumulative incidence of death free of hypoglycemia of 13.0%. Unfortunately, glycosylated hemoglobin levels were not recorded in the COIITSS trial, precluding an accurate assessment of the role of underlying diabetes mellitus in the risk of occurrence of hypoglycemia.

We assessed factors predictive of the cumulative incidence of first hypoglycemia, taking into account death prior to such an event as a competing risk. Univariable analyses used the Gray test based on the cumulative incidence approach, while multivariable analysis used the Fine and Gray model for subdistribution hazards.3 All analyses were performed at the 5% significance level from the cmprsk package in R version 2.10.1 (http://www.r-project.org). Among baseline variables, randomization to the tight glucose control group and blood glucose levels at or above 190 mg/dL (to convert to mmol/L, multiply by 0.0555) were the only variables independently associated with an increased cumulative incidence of hypoglycemia, whereas a

GUIDELINES FOR LETTERS. Letters discussing a recent JAMA article will have the best chance of acceptance if they are received within 4 weeks of the article’s publication date. Letters may have no more than 3 authors. They should not exceed 400 words of text and 5 references. Letters reporting original research should not exceed 600 words and 6 references. They may have no more than 5 authors. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters will be published at the discretion of the editors and are subject to editing and abridgment. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment is required for publication. Letters not meeting these specifications are generally not considered. Before submitting a Research Letter, please review the Instructions for Authors (http://jama.com/instructions). Letters should be submitted via the JAMA online submission and review system at http://manuscripts.jama.com (note: do not include “www” before the URL). For technical assistance, please contact jama-letters@jama-archives.org.

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

©2010 American Medical Association. All rights reserved.
Simplified Acute Physiology Score (SAPS) II of 60 or more had a protective association (Table). However, only the SAPS II was independently associated with a higher cumulative incidence of death prior to hypoglycemia, with an estimated subdistribution hazard ratio of 1.82 (95% confidence interval, 1.14-2.90). This suggests that the sickest patients died before hypoglycemia could occur, which would explain the decreased incidence of such an event in these patients.

Djillali Annane, MD
djillali.annane@rpc.ap-hop-paris.fr
University of Versailles SQY
Garches, France
Julie Lejeune, PharmD
Sylvie Chevet, MD
Hôpital Saint Louis, AP-HP
Paris, France

Financial Disclosures: None reported.


**Trends in Obesity and Extreme Obesity Among US Adults**

To the Editor: Using data from the National Health and Nutrition Examination Survey (NHANES), Dr Flegal and colleagues documented that, based on body mass index (BMI), the prevalence of overweight (BMI, 25–<30) and obesity (BMI ≥30) among adults in the United States in 2007-2008 was 68%. Additionally, a recent article suggested that another 10% of the US population may have normal weight obesity, defined as a high percentage of body fat despite a normal BMI (<25). Almost 80% of US adults may be carrying excess body fat, which may predispose them to chronic health problems. As the authors noted, extreme obesity is particularly important, given the association with increased mortality that is largely attributable to cardiovascular disease, diabetes mellitus, and malignancy. Therefore, we are particularly interested in the prevalence of grade 2 (BMI, 35–<40) and grade 3 (BMI ≥40) obesity (8.5% and 5.7%, respectively). It would be helpful to have information about changes in grade 2 and grade 3 obesity prevalence since 1999. It is possible that, even as obesity rates have plateaued, severe obesity rates have continued to increase.

Michael L. Main, MD
mmmain@cc.com
Seshu C. Rao, MD
James H. O’Keefe, MD
Saint Luke’s Mid America Heart Institute
Kansas City, Missouri

Financial Disclosures: None reported.


In Reply: In response to Dr Main and colleagues, we provide a Table that shows the age-standardized prevalence of grade 2 obesity (BMI of 35–<40), grade 3 obesity (BMI of

©2010 American Medical Association. All rights reserved.